Tofacitinib in Recurrent GBM Patients
| 대상 질환 | Glioblastoma |
|---|---|
| 임상 단계 | 3상 |
| 스폰서 | University of Texas Southwestern Medical Center |
| 상태 | 완료 |
| 참여자 수 | 18 명 |
| 중재(약물) | Tofacitinib 10mg, Temozolomide, Lomustine |
| 시작일 | 2022년 10월 7일 |
| 완료일 | 2025년 2월 18일 |
| 결과 공개일 | 2026년 6월 29일 |
요약
The purpose of this study is to examine the effects of Tofacitinib in patients with recurrent Glioblastoma.
Progression-free Survival (PFS) of the Study Cohort as Defined by RANO Criteria.
| Newly Diagnosed or Recurrent Off Temozolomide | 4 months |
|---|---|
| Recurrent Disease on Temozolomide | 4 months |
BENITIONS에서 보기 ClinicalTrials.gov 원문 보기
같은 질환의 다른 임상
- Solriamfetol in Improving Sleep in Patients With Grade II-IV Glioma — Wake Forest University Health Sciences
- Temozolomide With or Without Veliparib in Treating Patients With Newly Diagnosed Glioblast — National Cancer Institute (NCI)
- TORC1/2 Inhibitor MLN0128 and Bevacizumab in Treating Patients With Recurrent Glioblastoma — National Cancer Institute (NCI)
- Genetically Modified T-cells in Treating Patients With Recurrent or Refractory Malignant G — City of Hope Medical Center
- Phase II Study of BKM120 for Subjects With Recurrent Glioblastoma — L. Nicolas Gonzalez Castro, MD, PhD
- A Safety Study of Pharmacologic Ascorbate and Ferumoxytol in Addition to Standard of Care — Bryan Allen